DOCSLIB.ORG

Transcriptomics and Genomics in Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transcriptomics and Genomics in Prostate Cancer Transcriptomics and Genomics in Prostate Cancer Prof. Dr. Guido Jenster Experimental Urological Oncology Erasmus MC Rotterdam [email protected] Basic Research: The prostate cancer problem Transcriptomics and genomics of prostate cancer - What is the PCa problem and how to address it? - DNA sequencing - Common, rare and private mutations - Personalized Medicine - Metastasis - RNA sequencing - Small RNAs - Long RNAs - Liquid biopsies The prostate cancer problem How to address the prostate cancer problem: Early detection and cure via Hormone-, chemo-, immuno- Prevention surgery/radiation therapy therapy Bone metastasis Functional: Markers: Therapy targets: Understanding the -cancer risk? -which new medicines? components and -cancer present? -which order and combination? processes responsible -treatment needed? -therapy resistance? for cancer development -which treatment? and progression -treatment successful? Markers and therapy targets for prostate cancer Markers and therapy targets: An inventory of the differences between normal and cancer cells: Fusion genes DNA Gene mutations Novel RNAs RNA Small RNAs PCa nanobodies Protein Androgen receptor Metabolites Hormones Fatty acids Morphology Exosomes Cellular behavior Pathology / Imaging Genes and pathways responsible for prostate cancer initiation and progression TMPRSS2-ERG fusion PTEN inactivation Myc overexpression P53 AR inactivation amplification DNAseq Data Analysis Copy Number SNVs / InDels Abberations TF Binding B-Allele Frequency DNAseq data Chromatin Interactions Structural Variations Methylation Active Chromatin Identify Read Integration Sites Barcode PCa genomics: The messy genome FISH : chromosome painting In the messy cancer genomes, the secret of the tumor characteristics are hidden Van Bokhoven et al., The Prostate 57: 226-244 (2003) PCa genomics: The messy genome The Molecular Taxonomy of Primary Prostate Cancer How does this help an individual patient? TCGA, Cell 163, 4, 2015, Pages 1011–1025 PCa genomics: The messy genome TCGA, Cell 163, 4, 2015, Pages 1011–1025 Actionable targets PARP inhibitors Mateo et al., N Engl J Med. 2015 373(18):1697-708 PI3K and AKT inhibitors Kinase inhibitors Markers and therapy-targets for prostate cancer How many changes are identified in the VCaP cell line? On chromosome level: Breaks : 35 Base pair level: Breaks: 764 Small changes: 246,653 ~ 10 common ~ 20 rare ~ 500 proteins ~ 470 novel/private mutated Teles Alves et al., Human Genetics (2013) Markers and therapy-targets for prostate cancer The most common gene changes The most logical markers and therapy targets Majority and newly discovered Percentage tumors with gene change THADA MAP4K3 BRAF TMPRSS2-ERG MPP5-FAM71D ~50% ARHGEF3 LRBA RAF1 GPS2-MPP2 PRRT2 Common Rare Private The prostate cancer problem Personalized oncology / Precision medicine Search for changes in the tumor (such as DNA) that indicate: “Who should be treated when and with which medicines” Tumor type determines choice and order of therapy Type of DNA mutation and tumor type determine choice and order of therapy However, for many (rare/private) mutations we have no medicine PCa genomics: The messy genome The issue with heterogeneity and clonality Gundem et al., Nature 520: 353-357 (2015) PCa genomics: The messy genome Will the Personalized Medicine approach cure these patients? Gundem et al., Nature 520: 353-357 (2015) PCa genomics: Heterogeneity, clonal origin and re-population Cooper CS et al., Nat Genet. 2015 Apr;47(4):367-72. Su F et al., Eur Urol. 2018 Jun 22. pii: S0302-2838(18)30430-5 ‘All’ tumors represented: Biopsy Blood Urine Identify trunk mutations Primary tumor single cell sequencing Gundem et al., Nature 520: 353-357 (2015) PCa genomics: The messy genome The Molecular Taxonomy of Primary Prostate Cancer TCGA, Cell 163, 4, 2015, Pages 1011–1025 Basic Research: The prostate cancer problem Transcriptomics and genomics of prostate cancer - What is the PCa problem and how to address it? - DNA sequencing - Common, rare and private mutations - Personalized Medicine - Metastasis - RNA sequencing - Small RNAs - Long RNAs - Liquid biopsies Which type of RNA is most abundant? How many different genes do we have per type? Table 6-1 Molecular Biology of the Cell (© Garland Science 2008) Transcriptomics of PCa tissue: discovery of novel PCa-associated transcripts How many genes do humans have? 1) Up to 25,000 2) 25,000 – 60,000 3) 60,000 – 100,000 4) More than 100,000 RNAseq Data Analysis sdRNAs; tRFs PCA3 RNA modification Differential expression AR T877A ARv7 Alternative splicing & SNV / InDels RNAseq data Promoters Read-Through & Novel Transcripts Fusion Transcripts EPCAT176 (SChLAP1) TMPRSS2-ERG Small RNAs in prostate cancer progression Early detection and cure via Hormone-, chemo-, immuno- Prevention surgery/radiation therapy therapy Bone metastasis NAP: Normal Adjacent Prostate BPH: Benign Prostate Hyperplasia PCa: Organ-confined Prostate Cancer LN: PCa Lymph Node Metastases TURP-PCa: Castration Resistant PCa RNA pools of 4 fresh frozen patient samples for each group - size fractionation 18-35 nt - adaptor ligation, cDNA amplification and Solexa/Illumina sequencing (30-35 bp) Inventory of small RNAs in prostate and PCa samples Martens et al., Oncogene 2012;31(8):978-91. Families of small nucleolar RNA (snoRNA) snoRNA H/ACA-box snoRNA C/D-box scaRNAs PseudoUridylation of rRNA Methylation of rRNA Modification of RNA N= ±120 N= ±260 N= ±25 SNORA SNORD H/ACA and C/D-box snRNA Name Abbr. Function Size (nt) Post-transcriptional gene Micro RNA miRNA 21-24 regulation Small Nucleolar RNA snoRNA Modification of rRNAs 70-130 Small Cajal Body-specific RNAs scaRNA Modification of snRNAs 80-350 ? Hypothesis: Not only pre-miRNAs, but also other ncRNAs are specifically processed to smaller (functional ?) fragments snoRNAs from the GAS5 locus are up-regulated in prostate cancer GAS5 SNORDS NAP BPH PCa LN SNORD81 233 157 1,024 1,905 SNORD47 4 7 76 94 SNORD80 9 4 5 22 SNORD79 28 40 200 359 SNORD78 545 168 2,469 10,658 SNORD44 2,396 3,111 11,391 11,117 SNORD77 SNORD76 SNORD75 36 88 Prostate Cancer SNORD74 853 645 3,235 5,166 GAS5 mRNA 20 20 31 45 From Exon Arrays Normal adjacent prostate Martens-Uzunova ES et al., Oncotarget. 2015 Fragments generated from the GAS5 locus 05 32 07 300 08 404 11 117 11 846 800 325 800 405 Fragments generated from the GAS5 locus Basic Research: The prostate cancer problem Transcriptomics and genomics of prostate cancer - What is the PCa problem and how to address it? - DNA sequencing - Common, rare and private mutations - Personalized Medicine - Metastasis - RNA sequencing - Small RNAs - Long RNAs - Liquid biopsies A novel EMC Prostate Cancer-Associated Transcript (EPCAT) A novel EMC Prostate Cancer-Associated Transcript (EPCAT) Junction track Compilation of RNAseq reads 20 matched NAP 20 PCa Gene Left Gene Left EPCAT966 Gene Right Transcriptomics of PCa tissue: validation of novel PCa-associated transcripts Novel genes: Erasmus MC Prostate Cancer-Associated Transcripts EPCATs are long noncoding RNAs and not conserved Transcriptomics of PCa tissue: validation of novel PCa-associated transcripts No PCa: n=117 + 74 (cystoprostatectomy / pelvic exenteration / TURP BPH) Local PCa: n=481 Radical prostatectomy LN metastases: n=119 TURP-PCa: n=120 (65 CRPC; 55 HS) Böttcher R et al., Oncotarget. 2015 Feb 28;6(6):4036-50. Prostate Cancer Biomarkers: validation of novel PCa-associated transcripts PCa-associated transcripts (EPCATs) In situ hybridization EPCAT176 / SChLAP1 EPCAT176 overall survival Böttcher R. et al., Oncotarget. 2015 28;6(6):4036-50. Prostate Cancer Biomarkers: novel transcripts Prostate Cancer Biomarkers: novel transcripts Tissue-specific circRNAs PCa cells tissue Chen S, …Jenster G, ...Boutros P, He H, Cell in press Basic Research: The prostate cancer problem Transcriptomics and genomics of prostate cancer - What is the PCa problem and how to address it? - DNA sequencing - Common, rare and private mutations - Personalized Medicine - Metastasis - RNA sequencing - Small RNAs - Long RNAs - Liquid biopsies Prostate Cancer Research: Liquid biopsy CELL-FREE CIRCULATING TUMOR PROTEIN RNA CELLS METABOLITES CELL-FREE DNA EXTRACELLULAR VESICLES (EV-RNA; EV- PROTEINS; EV-DNA) PLATELETS VIRUSES MICRO- Urine ORGANISMS Serum Prostate Cancer Research: Liquid biopsy cell-free DNA Targeted cfDNA mutational analysis (72 mCRPC genes) WGS cfDNA mutational analysis (low pass) Wyatt AW et al., J Natl Cancer Inst. 2017 Dec 1;109(12) Viswanathan SR et al., Cell. 2018 Jul 12;174(2):433-447.e19 Diagnosis and prognosis of urogenital diseases The URINOME Project RNA and DNA from: Kidney Bladder Prostate Representing: Infection Cancer Stones Chronic disease Congenital diseases Transplantation Children, women and men ERG RNAseq of urine: TMPRSS2-ERG fusion transcript detected in a man with PCa Markers and therapy-targets for prostate cancer The most common gene changes The most logical markers and therapy targets Newly discovered Percentage tumors with gene change THADA MAP4K3 SKIL TMPRSS2-ERG PCATs/PCA3 MPP5-FAM71D ~50% sdRNAs ARHGEF3 LRBA HES6 circRNAs GPS2-MPP2 PRRT2 AR variants Common Biomarkers/Targets? Rare Private .
Load more

Recommended publications
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd
    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
    [Show full text]
  • Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis
    Figure S1. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. A Figure S1. Continued. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. B Figure S2. Comparative analysis of the variant frequency found by the KCC71 panel and calculated from publicly available cBioPortal datasets. For each of the 71 genes in the KCC71 panel, the frequency of variants was calculated as the variant number found in the examined cases. Datasets marked with different colors and sample numbers of prostate cancer are presented in the upper right. *Significantly high in the present study. Figure S3. Seven subnetworks extracted from each of seven public prostate cancer gene networks in TCNG (Table SVI). Blue dots represent genes that include initial seed genes (parent nodes), and parent‑child and child‑grandchild genes in the network. Graphical representation of node‑to‑node associations and subnetwork structures that differed among and were unique to each of the seven subnetworks. TCNG, The Cancer Network Galaxy. Figure S4. REVIGO tree map showing the predicted biological processes of prostate cancer in the Japanese. Each rectangle represents a biological function in terms of a Gene Ontology (GO) term, with the size adjusted to represent the P‑value of the GO term in the underlying GO term database.
    [Show full text]
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories
    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Looking for Missing Proteins in the Proteome Of
    Looking for Missing Proteins in the Proteome of Human Spermatozoa: An Update Yves Vandenbrouck, Lydie Lane, Christine Carapito, Paula Duek, Karine Rondel, Christophe Bruley, Charlotte Macron, Anne Gonzalez de Peredo, Yohann Coute, Karima Chaoui, et al. To cite this version: Yves Vandenbrouck, Lydie Lane, Christine Carapito, Paula Duek, Karine Rondel, et al.. Looking for Missing Proteins in the Proteome of Human Spermatozoa: An Update. Journal of Proteome Research, American Chemical Society, 2016, 15 (11), pp.3998-4019. 10.1021/acs.jproteome.6b00400. hal-02191502 HAL Id: hal-02191502 https://hal.archives-ouvertes.fr/hal-02191502 Submitted on 19 Mar 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Journal of Proteome Research 1 2 3 Looking for missing proteins in the proteome of human spermatozoa: an 4 update 5 6 Yves Vandenbrouck1,2,3,#,§, Lydie Lane4,5,#, Christine Carapito6, Paula Duek5, Karine Rondel7, 7 Christophe Bruley1,2,3, Charlotte Macron6, Anne Gonzalez de Peredo8, Yohann Couté1,2,3, 8 Karima Chaoui8, Emmanuelle Com7, Alain Gateau5, AnneMarie Hesse1,2,3, Marlene 9 Marcellin8, Loren Méar7, Emmanuelle MoutonBarbosa8, Thibault Robin9, Odile Burlet- 10 Schiltz8, Sarah Cianferani6, Myriam Ferro1,2,3, Thomas Fréour10,11, Cecilia Lindskog12,Jérôme 11 1,2,3 7,§ 12 Garin , Charles Pineau .
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Overview of Research on Fusion Genes in Prostate Cancer
    2011 Review Article Overview of research on fusion genes in prostate cancer Chunjiao Song1,2, Huan Chen3 1Medical Research Center, Shaoxing People’s Hospital, Shaoxing University School of Medicine, Shaoxing 312000, China; 2Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing 312000, China; 3Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou 310000, China Contributions: (I) Conception and design: C Song; (II) Administrative support: Shaoxing Municipal Health and Family Planning Science and Technology Innovation Project (2017CX004) and Shaoxing Public Welfare Applied Research Project (2018C30058); (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Song; (V) Data analysis and interpretation: H Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Chunjiao Song. No. 568 Zhongxing Bei Road, Shaoxing 312000, China. Email: [email protected]. Abstract: Fusion genes are known to drive and promote carcinogenesis and cancer progression. In recent years, the rapid development of biotechnologies has led to the discovery of a large number of fusion genes in prostate cancer specimens. To further investigate them, we summarized the fusion genes. We searched related articles in PubMed, CNKI (Chinese National Knowledge Infrastructure) and other databases, and the data of 92 literatures were summarized after preliminary screening. In this review, we summarized approximated 400 fusion genes since the first specific fusion TMPRSS2-ERG was discovered in prostate cancer in 2005. Some of these are prostate cancer specific, some are high-frequency in the prostate cancer of a certain ethnic group. This is a summary of scientific research in related fields and suggests that some fusion genes may become biomarkers or the targets for individualized therapies.
    [Show full text]
  • Expression of Periaxin (PRX) Specifically in the Human
    www.nature.com/scientificreports OPEN Expression of periaxin (PRX) specifcally in the human cerebrovascular system: PDZ Received: 6 November 2017 Accepted: 13 June 2018 domain-mediated strengthening Published: xx xx xxxx of endothelial barrier function Michael M. Wang1,2,3,4, Xiaojie Zhang1,2, Soo Jung Lee1,2, Snehaa Maripudi1,3, Richard F. Keep2,4,5, Allison M. Johnson4,6,7, Svetlana M. Stamatovic6,7 & Anuska V. Andjelkovic4,6,7 Regulation of cerebral endothelial cell function plays an essential role in changes in blood-brain barrier permeability. Proteins that are important for establishment of endothelial tight junctions have emerged as critical molecules, and PDZ domain containing-molecules are among the most important. We have discovered that the PDZ-domain containing protein periaxin (PRX) is expressed in human cerebral endothelial cells. Surprisingly, PRX protein is not detected in brain endothelium in other mammalian species, suggesting that it could confer human-specifc vascular properties. In endothelial cells, PRX is predominantly localized to the nucleus and not tight junctions. Transcriptome analysis shows that PRX expression suppresses, by at least 50%, a panel of infammatory markers, of which 70% are Type I interferon response genes; only four genes were signifcantly activated by PRX expression. When expressed in mouse endothelial cells, PRX strengthens barrier function, signifcantly increases transendothelial electrical resistance (~35%; p < 0.05), and reduces the permeability of a wide range of molecules. The PDZ domain of PRX is necessary and sufcient for its barrier enhancing properties, since a splice variant (S-PRX) that contains only the PDZ domain, also increases barrier function. PRX also attenuates the permeability enhancing efects of lipopolysaccharide.
    [Show full text]
  • Isolation and Identification of Proteins from Swine Sperm Chromatin and Nuclear Matrix
    DOI: 10.21451/1984-3143-AR816 Anim. Reprod., v.14, n.2, p.418-428, Apr./Jun. 2017 Isolation and identification of proteins from swine sperm chromatin and nuclear matrix Guilherme Arantes Mendonça1,3, Romualdo Morandi Filho2, Elisson Terêncio Souza2, Thais Schwarz Gaggini1, Marina Cruvinel Assunção Silva-Mendonça1, Robson Carlos Antunes1, Marcelo Emílio Beletti1,2 1Post-graduation Program in Veterinary Science, Federal University of Uberlandia, Uberlandia, MG, Brazil. 2Post-graduation Program in Cellular and Molecular Biology, Federal University of Uberlandia, Uberlandia, MG, Brazil. Abstract (Yamauchi et al., 2011). According to the same authors, these active sperm chromatin sites in protamine toroids The aim of this study was to perform a may contain important epigenetic information for the proteomic analysis to isolate and identify proteins from developing embryo. the swine sperm nuclear matrix to contribute to a The isolated use of genomic and transcriptomic database of swine sperm nuclear proteins. We used pre- information may be insufficient to fully understand a chilled diluted semen from seven boars (19 to 24 week- complex organism because proteomics and old) from the commercial line Landrace x Large White transcriptomics can be discordant and DNA-RNA x Pietran. The semen was processed to separate the relationships cannot be fully correlated. Thus, sperm heads and extract the chromatin and nuclear measurements of other metabolic levels should also be matrix for protein quantification and analysis by mass obtained, such as the study of proteins (Wright et al., spectrometry, by LTQ Orbitrap ELITE mass 2012). According to these same authors, large-scale spectrometer (Thermo-Finnigan) coupled to a nanoflow protein research in organisms (i.e., the proteome-protein chromatography system (LC-MS/MS).
    [Show full text]
  • Quantitative Trait Loci Mapping of Macrophage Atherogenic Phenotypes
    QUANTITATIVE TRAIT LOCI MAPPING OF MACROPHAGE ATHEROGENIC PHENOTYPES BRIAN RITCHEY Bachelor of Science Biochemistry John Carroll University May 2009 submitted in partial fulfillment of requirements for the degree DOCTOR OF PHILOSOPHY IN CLINICAL AND BIOANALYTICAL CHEMISTRY at the CLEVELAND STATE UNIVERSITY December 2017 We hereby approve this thesis/dissertation for Brian Ritchey Candidate for the Doctor of Philosophy in Clinical-Bioanalytical Chemistry degree for the Department of Chemistry and the CLEVELAND STATE UNIVERSITY College of Graduate Studies by ______________________________ Date: _________ Dissertation Chairperson, Johnathan D. Smith, PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, David J. Anderson, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Baochuan Guo, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Stanley L. Hazen, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Renliang Zhang, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Aimin Zhou, PhD Department of Chemistry, Cleveland State University Date of Defense: October 23, 2017 DEDICATION I dedicate this work to my entire family. In particular, my brother Greg Ritchey, and most especially my father Dr. Michael Ritchey, without whose support none of this work would be possible. I am forever grateful to you for your devotion to me and our family. You are an eternal inspiration that will fuel me for the remainder of my life. I am extraordinarily lucky to have grown up in the family I did, which I will never forget.
    [Show full text]
  • Identification of Potential Core Genes in Sevoflurance Induced Myocardial
    Identication of Potential core genes in Sevourance induced Myocardial Energy Metabolism in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery using Bioinformatics analysis Hua Lin ( [email protected] ) Tianjin Medical University General Hospital Airport Site Research article Keywords: sevourane, Myocardial Energy Metabolism, Off-pump Coronary Artery Bypass Graft Surgery Posted Date: November 18th, 2019 DOI: https://doi.org/10.21203/rs.2.17434/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Background: Myocardial ischemia-reperfusion injury always happened after Off-pump coronary artery bypass graft(OPCABG), and this can not be avoided altogether. In this study, we tried to detect potential genes of sevourane-induced myocardial energy metabolism in patients undergoing OPCABG using bioinformatics analysis. Methods: We download and analyze the gene expression prole data from the Gene Expression Omnibus(GEO) database using bioinformatics methods. We downloded the gene expression data from the Gene Expression Omnibus(GEO) database using bioinformatics methods. Gene Ontology(GO) functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis were used to analysis the screened differentially expressed genes(DEGs). Then, we established a protein–protein interaction (PPI) network to nd hub genes associated with myocardial energy metabolism. Results: Through PPI network, we nd ten hub genes, including JUN, EGR1, ATF3, FOSB, JUNB, DUSP1, EGR2, NR4A1, BTG2, NR4A2. Conclusions: In conclusion, the proteins encoded by EGR1ATF3c-FosBtg2JunBDUSP1NR4A1BTG2 and NR4A2 were related to cardiac function. ATF3, FOSB, JUNB, DUSP1, NR4A1, NR4A2 are related to apoptosis of cardiomyocytes. The protein encoded by BTG2 is related to hypertrophy.
    [Show full text]